Home›Trial›NCT06269133
NCT06269133ACTIVE NOT RECRUITING

Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Patients

Study Summary

This multi-year cohort study will assess the real-world safety and effectiveness of 1L treatment with cemiplimab in combination with platinum-doublet chemotherapy across advanced NSCLC patient subgroups defined by age, sex, race, and ethnicity. Patients will be retrospectively identified from at least two US electronic health record (EHR)-based databases.

Conditions
Advanced Non-small Cell Lung Cancer
Interventions / Drugs
REGN2810Platinum-doublet chemotherapy
View on ClinicalTrials.gov ↗
Sponsor
REGN
Regeneron Pharmaceuticals
Antibody Therapeutics
D47/100
Study Details
Enrollment1000 participants
Primary Completion—
Lead SponsorRegeneron Pharmaceuticals
Data Retrieved2026-04-11 02:55:54.866078+00:00
What This Trial Means for Biotech Investors
Trial Phase Context
Status & Expected Data

Enrollment is complete. The trial is in its follow-up or data collection phase — a readout may occur on or near the primary completion date.

Enrolled: 1,000 participants
Sponsor Catalyst Profile

Regeneron Pharmaceuticals (REGN) is the sponsoring company for this trial. BiotechSign currently grades this company D (47/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

REGN Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.